In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ACUITY:bivalirudin with/without GP IIbIIIa inhibitors

Acute Coronary Syndromes (ACS)


Analyses from long-term follow up of the landmark ACUITY trial presented today demonstrate that in moderate and high risk acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), treatment with bivalirudin alone resulted in significantly less bleeding at 30 days and comparable composite ischemia and mortality at 1 year than heparin (either unfractionated or enoxaparin) plus a glycoprotein IIb/IIIa inhibitor regardless of patient risk. The mortality results observed at 1 year with bivalirudin monotherapy were not dependent on the timing of clopidogrel administration.

Switching to bivalirudin monotherapy from prior treatment with unfractionated heparin or enoxaparin was also proven to be safe and effective, enabling patients to achieve the approximate 50% reduction in major bleeding while preserving similar protection from adverse ischemic outcome and death at 1 year.

PCI patients experiencing a non-CABG major bleed had a significantly longer length of hospital stay, 5.0 days vs 3.0 days (p<0.0001), compared with those that did not bleed. Further, a strong association was observed between early bleeding events and late mortality in ACS patients undergoing PCI.

These results suggest bivalirudin monotherapy should be the preferred adjunctive antithrombotic strategy in moderate and high risk ACS patients undergoing PCI and add to the evidence on the relationship between early bleeding and long-term outcome.





Clinical Trial Update I

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.